CORRIGENDA

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

H Gisslinger, G Jeryczynski, B Gisslinger, A Wölfle, S Burgstaller, V Buxhofer-Ausch, M Schalling, M-T Krauth, A-I Schiefer, C Kornauth, I Simonitsch-Klupp, C Beham-Schmid, L Müllauer and J Thiele

Leukemia (2017) 31, 774–775; doi:10.1038/leu.2016.291

Correction to: Leukemia (2016) 30, 1126–1132; doi:10.1038/leu.2015.360

Following the publication of this Article, the authors noted that there were errors in Tables 2 and 4. The correct tables are provided below—amended values highlighted in bold and italicised.

Further the authors confirmed that the last sentence of the third to last paragraph of the methods section should be amended to read ‘Antithrombotic therapy with low-dose aspirin was applied in 142 patients of the WHO-confirmed ET and 171 patients of the BCSH-defined ET cohort.’

The authors wish to apologize for any inconvenience caused.

Table 2. Clinical characteristics, molecular analysis and constitutional symptoms of patients with essential thrombocythemia (ET) at presentation and treatment according to applied diagnostic criteria

|                                | BCSH-defined ET (criteria A1–A3) | WHO-defined ET criteria | P-value |
|--------------------------------|----------------------------------|-------------------------|---------|
| General characteristics        |                                  |                         |         |
| n                              | 238                              | 232                     |         |
| Age at diagnosis (years)       | 61.3 (18.8–88.8)                 | 57.2 (17.5–88.8)        | 0.073   |
| Sex male/female                | 94/144                           | 93/139                  | 0.925   |
| Clinical characteristics*      |                                  |                         |         |
| Platelets (G/L)                | 769 (452–2530)                   | 754 (450–2490)          | 0.539   |
| Hemoglobin g/dl                | 14.2 (8.6–17.3)                  | 14.4 (8.6–17.3)         | 0.826   |
| Hematocrit (%)                 | 42.9 (42.9–52.0)                 | 42.7 (29.9–52.6)        | 0.630   |
| WBC (G/L)                      | 9.4 (2.21–31.32)                 | 8.82 (2.21–22.3)        | 0.057   |
| LDH (U/L)                      | 221 (118–763)                    | 207 (104–763)           | < 0.001 |
| Palpable splenomegaly ≥ 1      | 16.4% (39)                       | 11.9% (26)              | 0.183   |
| Fibrosis grading               | 8.4% (20)                        | 0.0% (0)                | < 0.001 |
| Molecular characteristics      |                                  |                         |         |
| Pathogenetic mutation present  | 100% (238)                       | 72.8% (169)             | –       |
| JAK2 V617F (238/220)b          | 72.7% (173)                      | 80.5% (136)             | 0.078   |
| CALR (181/141)b                | 24.4% (58)                       | 16.0% (27)              | 0.048   |
| MPL (75/53)b                   | 2.9% (7)                         | 3.5% (6)                | 0.780   |
| Symptoms at diagnosis          |                                  |                         |         |
| Constitutional symptoms (200/169)b | 16.0% (32)     | 14.8% (25)              | 0.774   |
| Weight loss                    | 4.5% (9)                         | 4.1% (7)                | 1.000   |
| Night sweats                   | 8.5% (17)                        | 8.3% (14)               | 1.000   |
| Fatigue                        | 5.0% (10)                        | 5.9% (10)               | 0.818   |
| Pruritus (202/175)b            | 2.0% (4)                         | 2.3% (4)                | 1.000   |
| Cytoxic therapy (191/164)b     |                                  |                         |         |
| Hydroxurea                     | 42.9% (82)                       | 42.1% (69)              | 0.494   |
| Interferon-alpha               | 34.6% (66)                       | 30.5% (50)              | 0.429   |
| Anagrelide                      | 30.4% (58)                       | 34.1% (56)              | 0.494   |
| JAK1/2-Inhibitor               | 4.7% (9)                         | 3.0% (5)                | 0.586   |
| Busulfan                       | 2.6% (5)                         | 2.4% (4)                | 1.000   |
| Others*                        | 4.2% (8)                         | 0.6% (1)                | 0.042   |
| Antithrombotic therapy         | 90.5% (171)                      | 88.8% (142)             | 0.602   |

Abbreviations: WBC, white blood cell count; LDH, serum lactate dehydrogenase. *Median, range. †Number evaluable in each cohort. ‡Pipobroman, P32 and other cytoxic agents.
Table 4. Clinical characteristics of patients with WHO-defined essential thrombocythemia (ET) compared with WHO-defined prefibrotic primary myelofibrosis (prePMF) at presentation as derived from the BCSH-conﬁrmed ET cohort

| Characteristics                      | WHO-deﬁned ET | WHO-deﬁned prePMF | P-value |
|--------------------------------------|---------------|-------------------|---------|
| General characteristics              |               |                   |         |
| n                                    | 141           | 77                |         |
| Age at diagnosis (years)             | 58.9 (18.8–88.8) | 64.6 (23.2–88.1) | 0.086   |
| Sex male/female                      | 58/83         | 27/50             | 0.486   |
| Clinical characteristics*            |               |                   |         |
| Platelets (G/L)                      | 725 (452–1836) | 840 (457–2530)    | 0.012   |
| Hemoglobin (g/dl)                    | 14.5 (11.5–17.3) | 13.9 (8.6–16.6)  | 0.007   |
| Hematocrit (%)                       | 43.0 (32.2–52.0) | 41.6 (27.5–48.9) | 0.036   |
| WBC (G/L)                            | 8.8 (2.2–21.1) | 10.3 (4.0–31.3)  | 0.004   |
| LDH (U/L)                            | 209 (110–763) | 270 (136–598)     | < 0.001 |
| Palpable splenomegaly (141/77)b      | 9.9% (14)     | 23.4% (18)        | 0.009   |
| Fibrosis grading ⩾ 1                 | 0.0% (0)      | 20.8% (16)        | < 0.001 |
| Molecular characteristics            |               |                   |         |
| Pathogenetic mutation present (141/77)b | 100% (141) | 100% (77)         | –       |
| JAK2 V617F (141/77)b                 | 78.0% (110)   | 61.0% (47)        | 0.011   |
| CALR (99/65)b                        | 19.2% (27)    | 35.1% (27)        | 0.013   |
| MPL (33/37)b                         | 2.8% (4)      | 3.9% (3)          | 0.700   |
| Symptoms at diagnosis                |               |                   |         |
| Constitutional symptoms (111/71)b    | 15.8% (16)    | 20.3% (10)        | 1.000   |
| Weight loss                          | 3.6% (4)      | 7.0% (5)          | 0.315   |
| Night sweats                         | 8.1% (9)      | 4.2% (3)          | 0.372   |
| Fatigue                              | 5.4% (6)      | 5.6% (4)          | 1.000   |
| Pruritus (111/71)b                   | 1.8% (2)      | 1.4% (1)          | 1.000   |
| Cytoreductive therapy (108/63)b      |               |                   |         |
| Hydroxyurea                          | 45.4% (49)    | 38.1% (24)        | 0.423   |
| Interferon-alpha                     | 31.5% (34)    | 34.9% (22)        | 0.736   |
| Anagrelide                           | 33.3% (36)    | 28.6% (18)        | 0.610   |
| JAK1/2-Inhibitor                     | 4.6% (5)      | 6.3% (4)          | 0.727   |
| Busulfan                             | 1.9% (2)      | 3.2% (2)          | 0.626   |
| Othersc                              | 0.9% (1)      | 6.3% (4)          | 0.062   |
| Antithrombotic therapy with low-dose aspirin (106/63)b | 89.6% (95) | 88.9% (56) | 1.000 |

Abbreviations: WBC, white blood cell count; LDH, serum lactate dehydrogenase. *Median, range. †Number evaluable in each cohort. ‡Pipobroman, P32 and other cytoreductive agents.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

CN Harrison, AM Vannucchi, J-J Kiladjian, HK Al-Ali, H Gisslinger, L Knoops, F Cervantes, MM Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna and T Barbui

*Leukemia* (2017) 31, 775; doi:10.1038/leu.2016.323

**Correction to:** *Leukemia* (2016) 30, 1701–1707; doi:10.1038/leu.2016.148

Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.

The authors wish to apologize for any inconvenience caused.